{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:04Z","timestamp":1761870964111,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.clml.2017.06.027","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T03:00:31Z","timestamp":1498532431000},"page":"595-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3362-8200","authenticated-orcid":false,"given":"Young-Woo","family":"Jeon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae-Hun","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo-Sung","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.06.027_bib1","first-page":"369","article-title":"How we treat tumor lysis syndrome","volume":"25","author":"Muslimani","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clml.2017.06.027_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ctrv.2009.11.001","article-title":"An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome","volume":"36","author":"Mughal","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2017.06.027_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1078155210364180","article-title":"Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome","volume":"17","author":"Knoebel","year":"2011","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2017.06.027_bib4","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/ndt\/gfp330","article-title":"A\u00a0novel role for uric acid in acute kidney injury associated with tumour lysis syndrome","volume":"24","author":"Shimada","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clml.2017.06.027_bib5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-2007-976175","article-title":"Tumor lysis syndrome","volume":"33","author":"Tiu","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clml.2017.06.027_bib6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.06.027_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","article-title":"Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review","volume":"95","author":"Howard","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.06.027_bib8","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.027_bib9","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3324\/haematol.13290","article-title":"Consensus conference on the management of tumor lysis syndrome","volume":"93","author":"Tosi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.06.027_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.06.027_bib11","first-page":"2273","article-title":"Postchemotherapy purine excretion in lymphoma patients receiving allopurinol","volume":"41","author":"Hande","year":"1981","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2017.06.027_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/14656566.3.4.433","article-title":"Rasburicase: a potent uricolytic agent","volume":"3","author":"Pui","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2017.06.027_bib13","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1200\/JCO.2003.04.115","volume":"21","author":"Coiffier","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.027_bib14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.leukres.2009.11.007","article-title":"Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia","volume":"34","author":"Karp","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.06.027_bib15","first-page":"2","article-title":"Highlights in B-cell malignancies from the 2012 American Society of Hematology (ASH) Meeting","volume":"11","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clml.2017.06.027_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-015-0224-3","article-title":"ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development","volume":"8","author":"Cang","year":"2015","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2017.06.027_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1078155214520821","article-title":"Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients","volume":"21","author":"Herrington","year":"2015","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.clml.2017.06.027_bib18","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/annonc\/mdr490","article-title":"A\u00a0randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome","volume":"23","author":"Vadhan-Raj","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.06.027_bib19","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1345\/aph.1P296","article-title":"Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients","volume":"44","author":"Vines","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clml.2017.06.027_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0609.2010.01457.x","article-title":"A\u00a0single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults","volume":"85","author":"Giraldez","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2017.06.027_bib21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/14656560902781972","article-title":"A\u00a0single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function","volume":"10","author":"Malaguarnera","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2017.06.027_bib22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/bmt.2010.212","article-title":"Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies","volume":"46","author":"Trifilio","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.06.027_bib23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","article-title":"Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma","volume":"19","author":"Pui","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.06.027_bib25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.amjmed.2003.09.045","article-title":"Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome","volume":"116","author":"Davidson","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2017.06.027_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.2830470212","article-title":"Acute spontaneous tumor lysis syndrome","volume":"47","author":"Jasek","year":"1994","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.06.027_bib27","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3109\/10428194.2013.874010","article-title":"Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?","volume":"55","author":"Canet","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.06.027_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.leu.2403566","article-title":"Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial","volume":"19","author":"Jeha","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.06.027_bib29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00277-003-0608-2","article-title":"Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma\/leukemia before and after introduction of prophylactic use of urate oxidase","volume":"82","author":"Wossmann","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.06.027_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/1042819021000054661","article-title":"Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries","volume":"44","author":"Annemans","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.06.027_bib31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0002-9343(75)90597-5","article-title":"American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival","volume":"58","author":"Arseneau","year":"1975","journal-title":"Am J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017301556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017301556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:09Z","timestamp":1761870549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017301556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S2152265017301556"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.027","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}